ERA-EDTA Operative Headquarters
Via XXIV Maggio 38
43123 Parma – Italy
Phone: +39 0521 989078
Fax: +39 0521 959242
E-mail: secretariat@era-edta.org
ERA-EDTA Registered Office
c/o PKF Littlejohn, 15 Westferry Circus, Canary Wharf
London E14 4HD – United Kingdom
Formulas that estimate GFR in diabetes: can we trust them? by Esteban Porrini
/in NDT-E Summary Articles /by ERA-EDTAGlobal epidemiology and outcomes of AKI with respect to CKD by Eric Adriaan J. Hoste
/in NDT-E Summary Articles /by ERA-EDTAHigh Altitude Medicine by Gianfranco Parati
/in NDT-E Summary Articles /by ERA-EDTAHDF versus medium cut-off dialyzers by Francisco Maduell
/in NDT-E Summary Articles /by ERA-EDTANutrition in patients with AKI: does it matter? by Enrico Fiaccadori
/in NDT-E Summary Articles /by ERA-EDTAHow to choose the right dialysis access for an individual patient by Maurizio Gallieni
/in NDT-E Summary Articles /by ERA-EDTAShould I change my daily practice in the treatment of lupus nephritis with new drugs for SLE? by Gabriella Moroni
/in NDT-E Summary Articles /by ERA-EDTAAKI in Covid-19 patients: mechanisms and management by Claudio Ronco
/in NDT-E Summary Articles /by ERA-EDTATreatment of dyslipidemia in CKD: where do we stand now? by Charles Ferro
/in NDT-E Summary Articles /by ERA-EDTAVitamin K in CKD patients: metabolism and therapeutic aspects by Jürgen Floege
/in NDT-E Summary Articles /by ERA-EDTACorticosteroids as first treatment in MCD, FSGS and IgAN: when and how. Long term side effects by Claudio Ponticelli
/in NDT-E Summary Articles /by ERA-EDTASGLT2 inhibition in CKD: Our chance to make a difference – Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca
/in NDT-E Summary Articles /by ERA-EDTAClinical Conundrums in aTypical HUS – Organised by ALEXION PHARMA GMBH
/in NDT-E Summary Articles /by ERA-EDTAK+: Recurrence, Restriction and Fluctuation. Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca
/in NDT-E Summary Articles /by ERA-EDTAExpert approaches to management across the CKD-MBD continuum – Organised by Vifor Fresenius Medical Care Renal Pharma Ltd.
/in NDT-E Summary Articles /by ERA-EDTACOVID-19 Registry – the Spanish experience by Emilio Sanchez
/in NDT-E Summary Articles /by ERA-EDTACOVID-19 infection – Some implications for nephrology by Annette Bruchfeld
/in NDT-E Summary Articles /by ERA-EDTACOVID-19 and ACE inhibitors and ARBs by Patrick Mark
/in NDT-E Summary Articles /by ERA-EDTAPersonalized diagnosis and CKD prediction in genetic tubular disorders by Francesca Becherucci
/in NDT-E Summary Articles /by ERA-EDTABiologic therapy in lupus nephritis – where are we now? by Gabriella Moroni
/in NDT-E Summary Articles /by ERA-EDTANew insights into pathogenesis and treatment of vascular calcification by Catherine Shanahan
/in NDT-E Summary Articles /by ERA-EDTAHistologic classification of lupus nephritis – time for a change by Ingeborg M. Bajema
/in NDT-E Summary Articles /by ERA-EDTASmall solute clearance: what are the pitfalls? by Enric Vilar
/in NDT-E Summary Articles /by ERA-EDTANew therapeutic targets in Alport syndrome by Roser Torra
/in NDT-E Summary Articles /by ERA-EDTAPhosphate toxicity in the kidney by Carsten Wagner
/in NDT-E Summary Articles /by ERA-EDTAVascular access : the Achilles tendon in HHD?
/in NDT-E Summary Articles /by ERA-EDTABariatric surgery: untangling the links between diabetes, hypertension and kidney disease?
/in NDT-E Summary Articles /by ERA-EDTAWhich method to measure GFR and in which clinical conditions?
/in NDT-E Summary Articles /by ERA-EDTAWhat is the optimal approach to the treatment of IgA nephropathy in 2019?
/in NDT-E Summary Articles /by ERA-EDTAOutcomes of frail patients after kidney transplantation
/in NDT-E Summary Articles /by ERA-EDTAANCA-associated vasculitis in the elderly and very elderly
/in NDT-E Summary Articles /by ERA-EDTASpecial issues of AKI and CKD in low and middle income countries by Mehmet Sukru Sever
/in NDT-E Summary Articles /by ERA-EDTAWhy is the risk of stroke so high in CKD and in dialysis patients? by Sydney Tang
/in NDT-E Summary Articles /by ERA-EDTAIs it time to consider dialysis withdrawal? by Monika Lichodziejewska-Niemierko
/in NDT-E Summary Articles /by ERA-EDTATherapeutic management of cystinuria: today and tomorrow by John Andrew Sayer
/in NDT-E Summary Articles /by ERA-EDTAKidney protection in living donors by Charles Ferro
/in NDT-E Summary Articles /by ERA-EDTAOxidative stress on myocardial function in CKD by Leticia Prates Roma
/in NDT-E Summary Articles /by ERA-EDTAAddressing potentially inappropriate medications in older adults with kidney disease by Rasheeda Hall
/in NDT-E Summary Articles /by ERA-EDTAPeritoneal dialysis adequacy and outcomes: what really matters? by Isaac Teitelbaum
/in NDT-E Summary Articles /by ERA-EDTAGut microbiota and microbial metabolism in CKD across stages of disease by Griet Glorieux
/in NDT-E Summary Articles /by ERA-EDTAMuscle protein turnover and low protein diet in patients with CKD by Giacomo Garibotto
/in NDT-E Summary Articles /by ERA-EDTADietary Acid Reduction and Kidney Protection: Adjunctive Benefits When Done with Fruits and Vegetables by Donald E. Wesson
/in NDT-E Summary Articles /by ERA-EDTAThe Concept of Incremental Dialysis by Carlo Basile
/in NDT-E Summary Articles /by ERA-EDTAAKI in austere environments by Valerie A. Luyckx
/in NDT-E Summary Articles /by ERA-EDTADo we still need calcineurin inhibitors in 2018? by Daniel Abramowicz
/in NDT-E Summary Articles /by ERA-EDTAConsulting the patient with AKI in other clinics: What should be stressed by a nephrologist? by Mustafa Arici
/in NDT-E Summary Articles /by ERA-EDTACyclophosphamide: the case of lupus nephritis – Should we still be using this old drug or does it have to be abandoned? by Vladimir Tesar
/in NDT-E Summary Articles /by ERA-EDTAContinuous renal replacement therapy by Roser Torra
/in NDT-E Summary Articles /by ERA-EDTAContinuous renal replacement therapy by Esteban Poch
/in NDT-E Summary Articles /by ERA-EDTAFrom the RNA world to the clinic: RNAs as drugs and drug targets by Bruce A. Sullenger
/in NDT-E Summary Articles /by ERA-EDTAAnti-GBM disease: New subgroups and novel therapies by Martin Segelmark
/in NDT-E Summary Articles /by ERA-EDTABack from the future – Lowering oral steroids in lupus therapy by Guillermo Ruiz-Irastorza
/in NDT-E Summary Articles /by ERA-EDTAKlotho and endocrine FGFs – marker of CKD progression and cardiovascular complications? By Makoto Kuro-o
/in NDT-E Summary Articles /by ERA-EDTAInflammation in crystal nephropathies by Hans-Joachim Anders
/in NDT-E Summary Articles /by ERA-EDTANew paradigms of the Kidney-Bone-Vascular axis in CKD by Klaus Olgaard
/in NDT-E Summary Articles /by ERA-EDTAThe conundrum of treating gout in patients with CKD by Jazub Zavada
/in NDT-E Summary Articles /by ERA-EDTACan antidiabetic drugs prevent chronic kidney disease progression? By Christoph Wanner
/in NDT-E Summary Articles /by ERA-EDTANewer agents in the treatment of SLE nephritis by David Jayne
/in NDT-E Summary Articles /by ERA-EDTA